Shares of Intellia Therapeutics (NASDAQ:NTLA) rose 6% after Citizens JMP Securities upgraded the stock from Market Perform to Market Outperform with a new $33 price target, citing a strengthened outlook for the company’s hereditary angioedema (HAE) program.
Analyst Silvan Tuerkcan, pointed to strong physician enthusiasm for Intellia’s once-and-done gene therapy candidate lonvo-z, based on a proprietary survey of U.S. allergist-immunologists. Survey results suggest lonvo-z could capture over 19% market share, translating into a $2.8 billion market opportunity.
Tuerkcan noted progress in the ongoing Phase 3 HAELO trial, which completed enrollment just nine months after the first patient was dosed in January 2025. Phase 2 data—expected by year-end—could act as a major catalyst, providing ~80% of the information content of the pivotal trial due in 2026.
Citizens also highlighted the potential of Intellia’s ATTR program, positioning it as a best-in-class one-time treatment with strong early efficacy and safety data. With a market cap of $2.1 billion and no long-term debt, Citizens believes NTLA is attractively valued, especially with $631 million in cash on hand to support further development.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.